Testing a new immunotherapy for chronic kidney transplant rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your kidney transplant must have been working for at least 6 months.
- Your kidney function (eGFR) must be 20 or higher.
- You must have certain antibodies targeting your donor kidney (called DSA).
- You must have a kidney biopsy showing chronic active antibody-mediated rejection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain immune cells (B cells) in the blood and kidney to better understand antibody-mediated rejection in kidney transplant patients. It might help doctors find new ways to diagnose or treat this type of rejection.
This trial tests a drug called BiTE to reduce high antibody levels (cPRA ≥90%) in people waiting for a kidney transplant. If it works, it might help you become eligible for a transplant sooner.
This trial tests a new two-step treatment for a type of long-term kidney rejection (chronic active antibody-mediated rejection) in transplant recipients. First, you receive an infusion of CD38 antibodies to clear harmful cells, then a months-long course of azathioprine pills to maintain the benefit and protect your kidney.
This trial tests a new approach to treat T-cell mediated rejection in kidney transplant recipients. It aims to safely and effectively stop the rejection episode.
This study tests a new medicine called SG301 to see if it can safely treat antibody-mediated rejection (a type of kidney rejection) in people who have had a kidney transplant. It may help stop the immune system from attacking the transplanted kidney.
This study tests whether a special immune therapy called a BiTE (bispecific T-cell engager) can safely help your body accept a kidney from a donor with a different blood type. It may reduce the need for strong anti-rejection medicines and improve transplant success.
Hear when a new Antibody Mediated Rejection After Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.